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Aim: To compare and evaluate the performance of two different volumetric modulated arc
therapy delivery techniques.
Background: Volumetric modulated arc therapy is a novel technique that has recently been
made available for clinical use. Planning and dosimetric comparison study was done for
Elekta VMAT and Varian RapidArc for different treatment sites.
Materials and methods: Ten patients were selected for the planning comparison study. This
includes 2 head and neck, 2 oesophagus, 1 bladder, 3 cervix and 2 rectum cases. Total dose
of  50 Gy was given for all the plans. All plans were done for RapidArc using Eclipse and
for  Elekta VMAT with Monaco treatment planning system. All plans were generated with
6  MV X-rays for both RapidArc and Elekta VMAT. Plans were evaluated based on the ability
to  meet the dose volume histogram, dose homogeneity index, radiation conformity index,
estimated radiation delivery time, integral dose and monitor units needed to deliver the
prescribed dose.
Results: RapidArc plans achieved the best conformity (CI95% = 1.08 ± 0.07) while Elekta VMAT
plans were slightly inferior (CI95% = 1.10 ± 0.05). The in-homogeneity in the PTV was high-
est  with Elekta VMAT with HI equal to 0.12 ± 0.02 Gy when compared to RapidArc with
0.08 ± 0.03. Signiﬁcant changes were observed between the RapidArc and Elekta VMAT
plans in terms of the healthy tissue mean dose and integral dose. Elekta VMAT plans
show  a reduction in the healthy tissue mean dose (6.92 ± 2.90) Gy when compared to
RapidArc (7.83 ± 3.31) Gy. The integral dose is found to be inferior with Elekta VMAT
(11.50 ± 6.49) × 104 Gy cm3 when compared to RapidArc (13.11 ± 7.52) × 104 Gy cm3. Both Var-
ian RapidArc and Elekta VMAT respected the planning objective for all organs at risk. Gamma
analysis result for the pre-treatment quality assurance shows good agreement between the
d ﬂuence for 3 mm DTA, 3% DD for all the evaluated points inside theplanned and deliverePTV, for both VMAT and RapidArc techniques.
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Conclusion: The study concludes that a variable gantry speed with variable dose rate is
important for efﬁcient arc therapy delivery. RapidArc presents a slight improvement in the
OAR sparing with better target coverage when compared to Elekta VMAT. Trivial differences
were noted in all the plans for organ at risk but the two techniques provided satisfactory
conformal avoidance and conformation.
© 2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All1.  Background
Approximately 50% of patients diagnosed for cancer receive
radiotherapy as a part of their oncologic management. So,
balancing the potential for early and late toxicity against
tumour control is particularly important. Intensity Modu-
lated Radiation Therapy (IMRT) has been revealed in several
instances to improve conformal avoidance when compared
to 3D conformal techniques for various sites. The availability
of more  sophisticated techniques like intensity- modulated
protons, helical tomotherapy and the newly  introduced volu-
metric modulated arc therapy (Elekta’s VMATTM and Varian’s
RapidArcTM), triggered interest in performing a new inves-
tigation to compare relevant dosimetric investigation when
applied to tough planning sites.1–5 These techniques are
believed to improve delivery efﬁciency compared to that of
IMRT  while maintaining similar treatment plan quality.4–6
Volumetric modulated arc therapy (VMAT) represents a
new paradigm in the treatment of patients with external beam
radiotherapy. VMAT  uses one or more  gantry arcs to deliver
dose from a range of coplanar or non-coplanar directions.
This new method of treatment delivery offers a challenge
to classical dosimetry protocols that involve static ﬁelds of
moderately large size. With VMAT,  the beams are dynamic in
orientation and aperture shape and may include small aper-
tures. The scatter conditions are expected to differ in such
beams, compared to classical open ﬁelds. So the calibration
carried out under broad-beam conditions may not be rele-
vant for VMAT.  The concept of rotational intensity-modulated
radiation therapy was ﬁrst described by Rock Mackie in 1993.
In 1995, Cedric Yu introduced an alternative approach to the
delivery of rotational IMRT. Arc therapy can be used as an alter-
native to tomotherapy as proposed by Yu.1 According to Yu,
with the increase in the number of gantry angles, the number
of intensity levels at each gantry angle can be reduced without
degrading plan quality. Also, arc therapy is efﬁcient in treating
a target wrapped around a critical structure, as demonstrated
by Cotrutz et al.18
Varian adopted Otto’s VMAT  algorithm (Otto, 2008) and
marketed it with the trade name, RapidArcTM (RA), in 2007.
Elekta started to market their product with the trade name
VMATTM. In this work, volumetric modulated arc therapy
delivery by Varian machine will be referred as “RapidArc”
and that of Elekta machine as “Elekta VMAT”. A recent
meta-analysis has suggested that intensity modulated treat-
ment delivery can reduce toxicities as compared to other
conventional and conformal type of deliveries. However,
the data regarding local control and overall survival are
inconclusive.7 With emerging data demonstrating the advan-
tages of IMRT,  future development in advanced radiationrights reserved.
delivery will include improvements in quality, efﬁciency, accu-
racy with the help of image  guidance.6 A major advancement
in intensity modulated arc therapy delivery was realized when
Otto implemented the volumetric modulated arc therapy
(VMAT) algorithm.4 Later, Yu et al.1,8 and Duthoy et al.9,10 ana-
lysed the beneﬁts of using multiple coplanar or noncoplanar
intensity-modulated arcs for complex treatments, demon-
strating that this new approach offers equivalent or superior
advantage. Recent studies by Bortfeld and Webb suggested
that a single-arc VMAT technique shows superior dosimetric
beneﬁts over intensity modulated radiotherapy, although we
have to accept a low dose spread over a large volume of tissue.
Both Varian and Elekta implemented arc therapy which allows
dose rate variations.
2.  Aim
The aim of the present study is to compare and evaluate the
plan quality, delivery efﬁciencies and performance of two dif-
ferent volumetric modulated arc therapy delivery techniques
for different treatment sites.
3.  Materials  and  methods
Ten cases were selected for the planning study. This included
2 head and neck, 2 oesophagus, 1 bladder, 3 cervix and 2 rec-
tum. Total dose of 50 Gy was given for all the plans. All selected
head and neck patients were post surgery cases. VMAT  and
RapidArc plans were generated for each of the cases, with
clinically relevant planning constraints. Planning parameters
were kept the same for both Elekta VMAT  and RapidArc. All
plans were evaluated based on the ability to meet the dose
volume histogram, dose homogeneity index, radiation confor-
mity index, estimated radiation delivery time, mean dose to
healthy tissues and integral dose, for both Elekta VMAT  and
Varian RapidArc. Also, all the plans were generated by a single
planner.
3.1.  RapidArc  planning  (Eclipse)
RapidArc plans were created in the Eclipse planning system,
which supports more  than one arc. All the RapidArc treat-
ment plans were created with 2 full arcs for 6 MV photons. The
ﬁrst arc was planned in the clockwise direction and second
in the counter clockwise direction. The maximum dose rate
was set at 600 MU/min. For all the plans, the collimator was
◦ ◦rotated between 30 and 45 to cover the entire tumour and
to reduce the tongue and groove effect.11 Couch parameters
were also added while planning to account for the attenu-
ation for mega voltage beams.12 The ﬁnal calculations were
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erformed using the Analytical anisotropic Algorithm (AAA).
he total numbers of control points are 177 for each arc. In
ersion 8.6, the optimization begins with 10 control points,
radually increasing to a maximum of 177. The arc optimiza-
ion algorithm, PRO (Progressive Resolution Optimizer) used in
apidArc, optimizes leaf position, dose rate and gantry speed.
he optimization is performed using progressive sampling in
ve resolution levels. In this version of the RapidArc planning,
he optimization appears to switch to next MR level before the
bjective function has converged for a given level. The opti-
ization can be paused in any resolution level by the planner.
 Millennium MLC  with 120 leaves with a spatial resolution of
 mm at isocentre was used. Varian’s MLC  is mounted on a car-
iage and acts as a tertiary collimator below the conventional
ollimator jaws.
.2.  Elekta  VMAT  planning  (Monaco)
olumetric modulated arc therapy planning for Elekta synergy
inac was done on the Monaco planning system, version 2.4.
ll VMAT  plans consist of only a single arc with 360◦ gantry
otation. All the plans were generated for 6 MV  photons with
 maximum dose rate kept at 600 MU/min. The collimator
as set at zero for all the plans. Elekta VMAT  does not imple-
ent Otto’s algorithm but uses a proprietary algorithm.13 The
onaco planning system optimizes treatment plans with the
id of sophisticated mathematical formulas, the cost func-
ions that model several different kinds of effects of desired
oal doses and their relationships for both targets and organs
t risk. Monaco offers constrained optimization. The cost
unctions predict the clinical effect of the treatment plan and
hen compare the acceptability of the plan to the optimization
bjectives and constraints. The optimization algorithm works
ithin parameters that impose several limits on the decision
ariables so that the dose delivered to the tumour is the max-
mum effective dose subject to given parameters. The VMAT
equencer uses a sweep sequencer because leaf speed is the
ost limiting factor of any modulated delivery. Even though
t requires more  MUs, the sweep sequencer minimizes leaf
ravel. This allows to avoid frequent beam stops, multiple arcs,
nd gantry moves without irradiation. Monte Carlo dose cal-
ulation algorithm is used for photon beam calculations. The
lekta MLC  assembly consists of 40 opposed pairs of leaves.
ach individual leaf projects to a width of 1 cm at the isocentre.
nlike with the Varian Millennium 120 leaf MLC, no leaf inter-
igitation is allowed for this type of design. Also the MLC on
he Elekta linac is a secondary collimator with x- and y-back-
p jaws placed under the MLCs. Each leaf can travel 12.5 cm
cross the centre and 20 cm from the centre. The back-up
ollimators always dynamically follow the MLC-shaped ﬁelds
nd lower the leakage radiation especially through the parked
aps. The minimum gap between the opposed leaves and the
pposed adjacent leaves was set to be 0.5 cm as suggested by
he vendor.
.3.  Radiation  delivery  (Varian)or Varian machines before the latest TrueBeam, the linac and
he MLC  are controlled by separate computers that interact
ith each other; the control points designed for treatmentiotherapy 1 8 ( 2 0 1 3 ) 87–94 89
delivery are decomposed into two groups of control param-
eters. (1) The MLC positions, as a function of delivered MUs,
are sent to the MLC  controller. (2) The gantry angle, as a func-
tion of cumulative MU, is sent as a segmented treatment table
to the linac control system, which translates the segmented
treatment table into commands that control the dose rate and
gantry speed during dynamic arc delivery. For Varian linacs
using a gridded gun, the instantaneous dose rate change in
their C-series of machines is performed by the dose rate servo
using pulse dropping. These older systems do not vary pulse
width.
3.4. Radiation  delivery  (Elekta)
For Elekta machines, the coordination between the MLC and
the linac delivery is performed by the ‘RT Desktop’. The meth-
ods of dose rate control are also different. For Elekta machines
employing a non-gridded gun, the dose rate is achieved by
varying the rate of the pulses and dose from each pulse is ﬁxed.
As a result, dose rates can be varied among discrete levels. The
dose rate is automatically calculated to be the maximum that
can be used without exceeding any of the movement  speeds
of leaves, jaws and the gantry. If the dose to be delivered in a
given interval is too high, the gantry and the leaves slow down
accordingly.
3.5. Evaluation  tools
Evaluation of the plans was performed by means of standard
DVH. For PTV D98% and D2% (dose received by the 98% and
2% of the volume) were deﬁned for minimum and maximum
doses. The homogeneity of the treatment plans was expressed
in terms of (D5% − D95%)/D50% (Homogeneity Index) according
to ICRU 83. The conformity of the plans was measured with
a conformity index, CI95% deﬁned as the ratio between the
patient volume receiving at least 95% of the prescribed dose
and the volume of the PTV. For organs at risk, the analysis
includes the mean dose and the maximum dose. For healthy
tissue, the integral dose, “doseInt”, is deﬁned as the integral of
the absorbed dose extended over all voxels but excluding those
within the target volume. Doses to relevant OARs were eval-
uated according to the speciﬁc treatment sites. Also, patient
speciﬁc quality assurance for all the treatment plans for both
RapidArc and Elekta VMAT techniques were done using 2D
array and Octavius Phantom. The TPS calculated ﬂuence was
compared to the delivered ﬂuence in phantom using PTW
verisoft. The acceptance criteria of 3 mm for the distance to
agreement (DTA) and dose difference tolerance level of 3%
were chosen for analysis. Also the percentage of the evalu-
ated dose points passing the gamma  index was kept at a limit
of greater than or equal to 95%.
3.6.  Gamma  analysis
Gamma  analysis is used to compare two 2D dose maps. Gen-
erally, the dose distribution comparison is sub divided into
regions of high and low dose gradients. In low gradient regions,
the doses are compared directly with an acceptance tolerance
placed on the difference between the two  dose maps. In high
dose gradient regions, a small spatial error, in either of the
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Table 1 – Dosimetric results for the PTV.
Parameter RapidArc VMAT P
D98% (Gy) 48.95 ± 1.05 47.66 ± 1.19 0.007
D2% (Gy) 54.54 ± 1.15 53.81 ± 1.22 0.170
HI 0.08 ± 0.03 0.12 ± 0.02 0.031
CI95% 1.08 ± 0.07 1.10 ± 0.05 0.377
MU 515.86 ± 125.61 640.43 ± 173.98 0.035
Table 3 – Head and neck—case study 1.
Parameter RapidArc VMAT
Brain max: dose (Gy) 44.72 47.72
D2% (Gy) 22.76 24.17
Cord max: dose (Gy) 35.69 37.17
D2% (Gy) 34.28 35.49
Left parotid mean dose (Gy) 21.94 23.54
D50% (Gy) 21.60 20.26
Right parotid mean dose (Gy) 22.20 21.93
D50% (Gy) 21.28 18.95
Larynx mean dose (Gy) 34.65 41.69
D50% (Gy) 33.97 41.53
Mandible max: dose (Gy) 54.91 52.28
Table 4 – Head and neck—case study 2.
Parameter RapidArc VMAT
Cord max: dose (Gy) 37.50 39.12
D2% (Gy) 35.45 36.82
Left parotid mean dose (Gy) 22.26 24.85
D50% (Gy) 21.72 20.38
Right parotid mean dose (Gy) 24.32 22.25
D50% (Gy) 22.65 19.84
Mandible max: dose (Gy) 52.25 50.73
Table 5 – Oesophagus—case study 1.
Parameter RapidArc VMAT
Cord max: dose (Gy) 36.76 33.22
D2% (Gy) 39.10 37.17
Lung mean dose (Gy) 18.07 15.41
V5 Gy (%) 89.22 89.04
V10  Gy (%) 88.03 84.90
V15  Gy (%) 71.18 44.36
V20  Gy (%) 35.95 22.45
V30  Gy (%) 9.09 7.22
V40  Gy (%) 1.11 1.51
Table 6 – Oesophagus—case study 2.
Parameter RapidArc VMAT
Cord max: dose (Gy) 37.36 39.57
D2% (Gy) 32.62 36.00
Heart mean dose (Gy) 21.39 26.33
D35% (Gy) 22.94 28.84
Lung mean dose (Gy) 22.03 15.25
V5 Gy (%) 83.22 82.74Beam on time (min) 2.59 ± 0.05 3.59 ± 0.56 0.007
P – paired t-test analysis: RapidArc vs. VMAT.
dose maps or small miss alignment results in large dose dif-
ference between the dose maps. Dose difference in the high
dose gradient regions may therefore be relatively unimportant
and the concept of DTA distribution is used to determine the
acceptability of agreement. The DTA is the distance between
a dose point in a dose map  and the nearest point in the other
dose map  that exhibits the same dose. The dose difference
and DTA evaluations complement each other when used as
determinants of agreement accuracy between the dose maps.
The simultaneous use of DTA and a percent dose difference
(DD) was proposed by Low et al.14. These parameters can help
evaluate the agreement of the two distributions in terms of
misalignment and difference, respectively. So in this study the
various gamma index constraints which are a combination of
particular DTA value with speciﬁc dose difference tolerance
value were used. In this study gamma  analysis was done for
the whole arc.
4.  Results  and  discussion
All plans sufﬁciently respected the planning objectives and
can be clinically accepted. Tables 1 and 2 provide an overview
of the numerical ﬁndings from an average DVH analysis
on PTV and healthy tissues which are reported as mean
values ± standard deviation (SD) to assess for the relative
inter-patient variability. Dosimetric results for organs at risk
(OAR) for all the ten patients were reported independently
as the analysis was done for different sites (Tables 3–12).
The results are very homogeneous within the different
approaches, as suggested by the small standard deviations
and frequent statistical signiﬁcance despite rather small abso-
lute differences. Both delivery techniques, if considered from
a clinical perspective appear to be equivalent. Figs. 1 and 2
show the treatment planning window for Varian RapidArc and
Elekta VMAT,  respectively.
V10  Gy (%) 81.85 75.98
V15  Gy (%) 79.36 46.95
V20  Gy (%) 65.74 23.94
V30  Gy (%) 23.66 9.03
Table 2 – Dosimetric results for healthy tissue.
Organ Parameter RapidArc VMAT  P
Healthy tissue Mean (Gy) 7.83 ± 3.31 6.92 ± 2.90 0.003
V2  Gy (%) 58.77 ± 12.41 46.87 ± 14.19 0.006
V5  Gy (%) 44.99 ± 13.63 34.09 ± 12.96 0.047
V10  Gy (%) 35.55 ± 12.98 23.00 ± 9.87 0.049
V20  Gy (%) 17.29 ± 8.09 12.28 ± 7.38 0.134
V30  Gy (%) 6.19 ± 3.18 5.18 ± 3.29 0.475
V40  Gy (%) 1.95 ± 1.24 1.64 ± 1.35 0.502
Int. dose (×104 Gy cm3) 13.11 ± 7.52 11.50 ± 6.49 0.010
P – paired t-test analysis: RapidArc vs. VMAT.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 87–94 91
lann
4
T
a
a
(Fig. 1 – RapidArc treatment p
.1.  Planning  target  volume  (PTV)arget coverage was almost similar for both RapidArc
nd Elekta VMAT  techniques. RapidArc plans resulted in
 better conformity (CI95% = 1.08 ± 0.07) than VMAT plans
CI95% = 1.10 ± 0.05). The dose inhomogeneity in PTV was
Fig. 2 – VMAT  treatment plannining window in Eclipse TPS.
higher for Elekta VMAT plans with HI equal to 0.12 ± 0.02
when compared to RapidArc with 0.08 ± 0.03. The average MU
(±SD) needed to deliver the dose of 200 cGy per fraction was
516 ± 126 MU for RapidArc and 640 ± 174 MU for Elekta VMAT.
The total number of segments for each RapidArc plan is 354.
For Elekta VMAT, the segments varied from 81 to 213, with a
g window in Monaco TPS.
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Fig. 3 – Gamma  analysis results for the PTV for both RapidArc and Elekta VMAT.
Table 7 – Bladder—case study 1.
Parameter RapidArc VMAT
Rectum mean dose (Gy) 20.84 25.36
D30% (Gy) 22.77 27.85
Femoral head left mean dose (Gy) 22.94 13.31
D15% (Gy) 27.18 20.84
Femoral head right mean dose (Gy) 22.50 13.15
D15% (Gy) 26.98 20.04
Table 8 – Cervix—case study 1.
Parameter RapidArc VMAT
Rectum mean dose (Gy) 36.76 33.22
D30% (Gy) 39.10 37.17
Femoral head mean dose (Gy) 22.17 11.05
D15% (Gy) 29.22 14.31
Bladder mean dose (Gy) 36.42 31.31
D35% (Gy) 38.14 35.40
Table 9 – Cervix—case study 2.
Parameter RapidArc VMAT
Rectum mean dose (Gy) 29.65 35.18
D30% (Gy) 33.25 39.91
Femoral head mean dose (Gy) 24.73 14.96
D15% (Gy) 29.87 22.75
Bladder mean dose (Gy) 30.40 31.93
D35% (Gy) 32.24 35.69
Table 10 – Cervix—case study 3.
Parameter RapidArc VMAT
Rectum mean dose (Gy) 32.73 37.58
D30% (Gy) 32.25 38.25
Femoral head mean dose (Gy) 26.20 16.55
D15% (Gy) 31.41 24.23
Bladder mean dose (Gy) 32.15 33.42
D35% (Gy) 35.26 36.68
Table 11 – Rectum—case study 1.
Parameter RapidArc VMAT
Femoral head left mean dose (Gy) 23.07 21.11
D15% (Gy) 28.99 30.20
Femoral head right mean dose (Gy) 23.73 18.54
D15% (Gy) 30.33 27.94
Bladder mean dose (Gy) 33.30 29.37
D35% (Gy) 35.11 31.73
standard deviation of ± 43.92 between the plans. The radiation
beam on time (after patient setup) was 2.52–2.64 min  for Rapi-
dArc and 2.82–4.22 min  for Elekta VMAT. The average beam on
time for all RapidArc plans (2.59 ± 0.05) was found to be signif-
icantly lower when compared with Elekta VMAT  (3.59 ± 0.56).
Also the gamma  analysis result for the pre-treatment quality
assurance shows good agreement with the planned and deliv-
ered ﬂuence for 3 mm DTA, 3% DD for all the evaluated points
inside the PTV, for both Elekta VMAT and RapidArc techniques.
The percentage dose points failed the gamma criteria by less
than 5% in the analysed area. The results were displayed in
Fig. 3.Table 12 – Rectum—case study 2.
Parameter RapidArc VMAT
Femoral head left mean dose (Gy) 24.55 22.75
D15% (Gy) 26.80 27.50
Femoral head right mean dose (Gy) 24.53 20.64
D15% (Gy) 30.55 28.13
Bladder mean dose (Gy) 32.72 30.55
D35% (Gy) 33.84 30.04
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.2. Healthy  tissue
igniﬁcant changes were observed between the RapidArc and
lekta VMAT  plans in terms of the mean dose and integral
ose. The Integral dose is computed as the mean dose times
he volume of healthy tissue irradiated. VMAT  plans show
 reduction in the healthy tissue mean dose (6.92 ± 2.90) Gy
hen compared to RapidArc (7.83 ± 3.31) Gy. The integral dose
s found to be lower with VMAT  (11.50 ± 6.49) × 104 Gy cm3
hen compared to RapidArc (13.11 ± 7.52) ×104 Gy cm3. Also
lekta VMAT  plans show a reduction in the volume of healthy
issue irradiation at lower doses mainly with a reduction
bserved at V10 Gy (35.55 ± 12.98 with RapidArc and 23.00 ± 9.87
ith Elekta VMAT), V5 Gy (44.99 ± 13.63 with RapidArc and
4.09 ± 12.96 with Elekta VMAT), V2 Gy (58.77 ± 12.41 with Rap-
dArc and 46.87 ± 14.19 with Elekta VMAT)  when compared to
apidArc plans.
.3.  Organs  at  risk
oth the technique satisﬁed the planning objective for all
rgans at risk. The different characteristics of patients prevent
he possibility to present an average conclusion and therefore
he analysis was done separately for all the cases. The results
re displayed in Tables 3–12.
This study demonstrates that treatment techniques differ
n terms of the trade-off between treatment planning time,
reatment delivery time, and overall plan quality. It is true
hat IMRT  treatment plans can be created in a much shorter
eriod of time as compared to either Elekta VMAT  or RapidArc
lans, but has the lowest estimated treatment delivery time
ompared to IMRT.  Also with respect to plan quality, RapidArc
ppears to meet the most dose–volume criteria and can, on
verage, produce plans with the most homogeneity within the
arget volume. The conformity indices show that RapidArc is
etter than Elekta VMAT,  but the difference does not appear
o be clinically signiﬁcant. Both RapidArc and Elekta VMAT
pare critical structures by redistributing the normal tissue
ose to less critical regions and reducing the high dose vol-
me  to cover just the target. Elekta VMAT  shows superiority
n delivering less dose to healthy tissues particularly in the
ower volumes. Signiﬁcant reductions of dose to healthy tis-
ues were observed with Elekta VMAT  at V10 Gy, V5 Gy, V2 Gy. The
eason may be the jaw tracking capability during delivery. This
an also reduce the interleaf leakage in Elekta VMAT delivery.
lso for beam collimation systems in which the jaws cannot
rack the MLC-shaped apertures, the gap between the closed
pposing leaves outside the aperture gives additional leak-
ge radiation. If the collimator angle is ﬁxed at zero, leaving
he gap parallel with the rotational axis, the leakage radiation
rom the gap will be focused on the rotational axis or form
 cylindrical high dose shell around the rotational axis out-
ide the target. One way to spread this leakage dose is to set
he appropriate collimator angle during planning. So, all the
apidArc plans were generated by setting a collimator angle
etween 30◦ and 45◦. The ability of rotating the collimator
ngle during delivery may increase the optimization free-
om and produce a better plan quality as proposed by Zhang
t al.19 Webb20 demonstrated that if the collimator angle
s also included as an optimization parameter, additionaliotherapy 1 8 ( 2 0 1 3 ) 87–94 93
freedom can be gained for improved deliverability, leading to
a reduction in the number of parked gaps and unwanted leak-
age dose. The latest machine from Varian (True Beam) with
the jaw tracking ability will be able to deliver lesser dose to
the normal structures.
The intercomparison of data from different treatment
planning systems may be stringent due to a number of com-
plicating issues.15 A single arc delivered in less than 2 min  may
unduly compromise the plan quality for very complex cases
and feel that the plan quality for Elekta VMAT  and RapidArc
are similar. For RapidArc, the estimated treatment delivery
time is the sum of the time spent at each of the 177 segments
within an arc. The time is the sum of all angular increments
per segment divided by the gantry rotation rate. All the Rap-
idArc cases in this study were planned using double arc. The
use of two arcs was found to be necessary to achieve the
high degree of conformal avoidance required by the planning
objective. Adding a second arc provided the planning sys-
tem with additional freedom for achieving better treatment
plans.16 This is especially true for MLCs which cannot (geo-
metrically) cover a large target with one dynamic sequence.
For tumours that are not centrally located and surrounded
by parallel organs, the use of partial arcs is often desirable.
For tumours in the brain and in the head-and-neck region, it
is often advantageous to use multiple non-coplanar arcs for
better tumour targeting and critical structure avoidance. In
principle, the more  freedom we give to the planning system,
the better quality of plans can be generated. However, with
photon beams, there is a limit to the treatment plan quality.
This limit is often not set by the degree of intensity modu-
lation but by the physics of photon dose deposition. Also, it
should be noted that there are many  other issues in addi-
tion to plan quality that are associated with different delivery
techniques. These include the efﬁciency of planning, delivery,
quality assurance (QA), the complexity and reliability of deliv-
ery, and the total MUs required in delivering the prescribed
doses and the total leakage radiation received by the patient
outside the target region.
Both Elekta VMAT and RapidArc plans show clinically
acceptable plan quality, but each technique has its advan-
tages and shortcomings in different types of cases. The
inﬂuence of more  efﬁcient modulated approaches such as
VMAT on secondary cancer risk is not clear to date. But the
improved treatment efﬁciency may reduce secondary malig-
nancies due to less scatter dose from reducing the MUs. A
different characteristic of the dose distribution with higher
non-target tissue receiving 5–40 Gy with the VMAT  technique
may well increase the number of secondary malignancies.17
Duthoy et al. could perform VMAT  for large volumes with
four rotations in patients to undergo a whole abdomen and
pelvic radiation therapy with a mean treatment time of
13.8 min  with only 444 MU for a fraction dose of 1.5 Gy.10 The
same author reported treatment time of 6.3 min  (3–6 arcs
and 456 MU) for 7 patients with rectal cancer at a prescrip-
tion dose of 1.8 Gy.9 While no formal comparison with IMRT
was made, these data implied the potential of the rotational
approach. Both the Elekta VMAT and RapidArc algorithms
used in this study are robust and can produce plans that can
cover any complex and large targets with a high degree of
conformity.
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5.  Conclusion
It is well known that planning comparisons such as our study
are susceptible to bias. It should be stressed that this study
will not give a general conclusion about superiority of one
technique or the other, but results have to be interpreted in
the context of the speciﬁc planning algorithm and study pro-
tocol. The study demonstrated that the variable gantry speed
with variable dose rate is important for efﬁcient arc therapy
delivery. RapidArc plans had less estimated beam on time,
higher conformity index and better homogeneity index. The
mean dose to healthy tissue and integral dose reduced sig-
niﬁcantly with Elekta VMAT.  The conclusions of this study
are that the two techniques are practically equivalent. Triv-
ial differences were noted in all the plans for organ at risk but
the two techniques provided satisfactory conformal avoidance
and conformation.
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